Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
暂无分享,去创建一个
David Verbel | Lawrence Schwartz | Steven M Larson | Homer Macapinlac | Karen L. Siedlecki | S. Larson | L. Schwartz | M. Morris | H. Scher | H. Macapinlac | I. Osman | K. Siedlecki | T. Akhurst | D. Verbel | R. Nunez | Howard I Scher | Timothy Akhurst | Iman Osman | Michael J Morris | Rodolfo Nunez | Karen Siedlecki
[1] Q. Mcnemar. Note on the sampling error of the difference between correlated proportions or percentages , 1947, Psychometrika.
[2] G Jakse,et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.
[3] J E Oesterling,et al. PSA and staging of localized prostate cancer. , 1993, The Urologic clinics of North America.
[4] W. Nelson,et al. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! , 1996, Journal of the National Cancer Institute.
[5] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[6] R. Wahl,et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.
[7] M Mazumdar,et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Belldegrun,et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. , 1999, The Journal of urology.
[9] H. Schirrmeister,et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures , 2001, European Journal of Nuclear Medicine.
[10] A Donner,et al. Application of the McNemar test to non-independent matched pair data. , 1991, Statistics in medicine.
[11] H. Groen,et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.
[12] T. Wheeler,et al. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.
[13] T. Block,et al. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy , 1999, European Urology.
[14] M. Welch,et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Dawson. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Terris,et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. , 2001, Urology.
[17] M Mazumdar,et al. Clinical trials in relapsed prostate cancer: defining the target. , 1996, Journal of the National Cancer Institute.
[18] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Sanz,et al. Positron emission tomography with 18fluorine‐labelled deoxyglucose: utility in localized and advanced prostate cancer , 1999, BJU international.
[20] S. Larson,et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. , 1996, Nuclear medicine and biology.
[21] K S Panageas,et al. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. , 2001, Radiology.
[22] H. Scher,et al. Clinical states in prostate cancer: toward a dynamic model of disease progression. , 2000, Urology.
[23] P. Robinson,et al. Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer , 1990, Cancer.
[24] M. J. Fusselman,et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. , 1996, Radiology.
[25] H. Müller-Gärtner,et al. Staging of Pelvic Lymph Nodes in Neoplasms of the Bladder and Prostate by Positron Emission Tomography with 2-[18F]-2-Deoxy-D-Glucose , 1999, European Urology.
[26] R. Coleman,et al. Pulmonary abnormalities and PET data analysis: a retrospective study. , 1997, Radiology.